LED Medical develops risk assessment test for oral cancer

Source: Dr. BicuspidPublished: January 16, 2014By: Donna Domino    LED Medical Diagnostics has signed an agreement with the BC Cancer Agency to form a collaborative relationship with Genome British Columbia (Genome BC) to create and commercialize a progression risk assessment test for oral cancer. The test, which is the first genetic test for oral cancer, is based on a quantifiable genetic phenomenon known as "loss of heterozygosity" (LOH), the most common molecular genetic alteration observed in human cancers. LOH refers to genetic information that shows if a cell has developed into an abnormal state (dysplasia) and predicts what the outcome of the dysplasia will be, LED Medical Diagnostics' founder and director, Peter Whitehead, explained in an interview with DrBicuspid.com. "The test will show whether or not the dysplasia is going to turn into something you need to remove immediately or something you need to be concerned about and just watch," he said. The test will use the same technology that screened and diagnosed actress Angelina Jolie's breast cancer risk, Whitehead noted. "She had a hereditary high-risk gene, and the lump in her breast had lots of heterozygosity. They removed her breast based on the fact that the LOH in that tumor was high-risk," Whitehead said. "LOH has been around for a while, but no one has translated it from lab bench to a clinical test." When a patient is diagnosed with moderate dysplasia, they usually must see a specialist every six months for five years because there's a chance the dysplasia [...]